JP2020512387A - 代謝性障害の治療の為の置換シクリル酢酸誘導体 - Google Patents

代謝性障害の治療の為の置換シクリル酢酸誘導体 Download PDF

Info

Publication number
JP2020512387A
JP2020512387A JP2019554000A JP2019554000A JP2020512387A JP 2020512387 A JP2020512387 A JP 2020512387A JP 2019554000 A JP2019554000 A JP 2019554000A JP 2019554000 A JP2019554000 A JP 2019554000A JP 2020512387 A JP2020512387 A JP 2020512387A
Authority
JP
Japan
Prior art keywords
group
methoxy
compound
mixture
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019554000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512387A5 (https=
Inventor
誠司 見渡
誠司 見渡
泰史 宮本
泰史 宮本
浩史 渡部
浩史 渡部
弥生 中山
弥生 中山
優子 人見
優子 人見
淳平 会田
淳平 会田
信幸 ▲高▼倉
信幸 ▲高▼倉
英紀 古川
英紀 古川
直義 野口
直義 野口
泰啓 平田
泰啓 平田
静夫 河西
静夫 河西
俊威 小林
俊威 小林
前川　毅志
毅志 前川
佐々木　聡
聡 佐々木
重充 松本
重充 松本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Scohia Pharma Inc
Original Assignee
Takeda Pharmaceutical Co Ltd
Scohia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd, Scohia Pharma Inc filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2020512387A publication Critical patent/JP2020512387A/ja
Publication of JP2020512387A5 publication Critical patent/JP2020512387A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019554000A 2017-03-31 2018-03-29 代謝性障害の治療の為の置換シクリル酢酸誘導体 Ceased JP2020512387A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017072813 2017-03-31
JP2017072813 2017-03-31
PCT/JP2018/014501 WO2018182050A1 (en) 2017-03-31 2018-03-29 Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders

Publications (2)

Publication Number Publication Date
JP2020512387A true JP2020512387A (ja) 2020-04-23
JP2020512387A5 JP2020512387A5 (https=) 2021-04-30

Family

ID=62116518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019554000A Ceased JP2020512387A (ja) 2017-03-31 2018-03-29 代謝性障害の治療の為の置換シクリル酢酸誘導体

Country Status (10)

Country Link
US (1) US10968231B2 (https=)
EP (1) EP3601260A1 (https=)
JP (1) JP2020512387A (https=)
KR (1) KR20190136049A (https=)
CN (1) CN110678458A (https=)
AR (1) AR111199A1 (https=)
CA (1) CA3058588C (https=)
MX (1) MX2019011782A (https=)
TW (1) TW201841920A (https=)
WO (1) WO2018182050A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023106310A1 (ja) * 2021-12-07 2023-06-15 塩野義製薬株式会社 Ｇｌｐ－１受容体アゴニスト活性を有する芳香族複素環誘導体
JP2023527980A (ja) * 2020-05-26 2023-07-03 エスアルファセラピューティクス，インコーポレーテッド 癌悪液質治療のためのデジタル装置およびアプリケーション、並びにその使用方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2018181847A1 (ja) 2017-03-31 2020-03-05 武田薬品工業株式会社 芳香環化合物
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US12516036B2 (en) 2019-05-31 2026-01-06 Hyundai Pharm Co., Ltd. Crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
IL295825A (en) 2020-02-28 2022-10-01 Kallyope Inc gpr40 agonists
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN112830933A (zh) * 2021-02-04 2021-05-25 康化（上海）新药研发有限公司 一种3,4-二氢-2H-吡喃并[2,3-b]吡啶合成方法
KR102699076B1 (ko) * 2021-04-01 2024-08-27 현대약품 주식회사 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041266A1 (ja) * 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited 受容体機能調節剤
JP2005343792A (ja) * 2003-05-30 2005-12-15 Takeda Chem Ind Ltd 縮合環化合物
JP2009530281A (ja) * 2006-03-14 2009-08-27 アムジエン・インコーポレーテツド 代謝障害の治療に有用である二環式カルボン酸誘導体
JP2011515341A (ja) * 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体
JP2012505896A (ja) * 2008-10-15 2012-03-08 アムジエン・インコーポレーテツド スピロ環ｇｐｒ４０調節因子
JP2013523819A (ja) * 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
WO2015020184A1 (ja) * 2013-08-09 2015-02-12 武田薬品工業株式会社 芳香環化合物
WO2018181847A1 (ja) * 2017-03-31 2018-10-04 武田薬品工業株式会社 芳香環化合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2002006234A1 (en) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Sulfone derivatives, process for their production and use thereof
NZ540381A (en) 2002-11-01 2007-11-30 Takeda Pharmaceutical 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy
AU2003284596A1 (en) 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
AU2004309271A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
EP1698624B1 (en) 2003-12-26 2012-06-27 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
JPWO2007013694A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
KR20080033524A (ko) 2005-08-10 2008-04-16 다케다 야쿠힌 고교 가부시키가이샤 당뇨병 치료제
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
BRPI0713378A8 (pt) 2006-06-27 2018-01-02 Takeda Pharmaceutical composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto
EP2077267A4 (en) 2006-10-18 2010-04-07 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
US7652133B2 (en) 2006-10-19 2010-01-26 Takeda Pharmaceutical Company Limited Indole compound
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
EP2118066A1 (en) 2007-02-09 2009-11-18 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
CN102083783A (zh) 2007-10-10 2011-06-01 安姆根有限公司 取代的联苯gpr40调节剂
US9181186B2 (en) 2012-02-13 2015-11-10 Takeda Pharmaceutical Company Limited Aromatic ring compound
US9920040B2 (en) 2015-08-12 2018-03-20 Janssen Pharmaceutica Nv GPR40 agonists for the treatment of type II diabetes
US9908873B2 (en) 2015-08-12 2018-03-06 Janssen Pharmaceutica Nv GPR40 agonists for the treatment of type II diabetes
WO2017027312A1 (en) 2015-08-12 2017-02-16 Janssen Pharmaceutica Nv Gpr40 agonists for the treatment of type ii diabetes
JP6627397B2 (ja) 2015-10-09 2020-01-08 富士通オプティカルコンポーネンツ株式会社 光モジュール及び光伝送装置
WO2017172505A1 (en) 2016-03-29 2017-10-05 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2018081047A1 (en) 2016-10-25 2018-05-03 Janssen Pharmaceutica Nv Cyclohexyl gpr40 agonists for the treatment of type ii diabetes
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041266A1 (ja) * 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited 受容体機能調節剤
JP2005343792A (ja) * 2003-05-30 2005-12-15 Takeda Chem Ind Ltd 縮合環化合物
JP2009530281A (ja) * 2006-03-14 2009-08-27 アムジエン・インコーポレーテツド 代謝障害の治療に有用である二環式カルボン酸誘導体
JP2011515341A (ja) * 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体
JP2012505896A (ja) * 2008-10-15 2012-03-08 アムジエン・インコーポレーテツド スピロ環ｇｐｒ４０調節因子
JP2013523819A (ja) * 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
WO2015020184A1 (ja) * 2013-08-09 2015-02-12 武田薬品工業株式会社 芳香環化合物
WO2018181847A1 (ja) * 2017-03-31 2018-10-04 武田薬品工業株式会社 芳香環化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DU,X. ET AL.: "Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists", ACS MEDICINAL CHEMISTRY LETTERS, vol. 5, no. 4, JPN6021038145, 2014, pages 384 - 389, ISSN: 0004608760 *
NEGORO,N. ET AL.: "Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist", ACS MEDICINAL CHEMISTRY LETTERS, vol. 1, no. 6, JPN6021038142, 2010, pages 290 - 294, ISSN: 0004608762 *
WANG,Y. ET AL.: "Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles", ACS MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 6, JPN6021038143, 2013, pages 551 - 555, ISSN: 0004608761 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023527980A (ja) * 2020-05-26 2023-07-03 エスアルファセラピューティクス，インコーポレーテッド 癌悪液質治療のためのデジタル装置およびアプリケーション、並びにその使用方法
JP7592106B2 (ja) 2020-05-26 2024-11-29 エスアルファセラピューティクス，インコーポレーテッド 癌悪液質治療のためのデジタル装置およびアプリケーション、並びにその使用方法
WO2023106310A1 (ja) * 2021-12-07 2023-06-15 塩野義製薬株式会社 Ｇｌｐ－１受容体アゴニスト活性を有する芳香族複素環誘導体

Also Published As

Publication number Publication date
CN110678458A (zh) 2020-01-10
WO2018182050A1 (en) 2018-10-04
US10968231B2 (en) 2021-04-06
TW201841920A (zh) 2018-12-01
KR20190136049A (ko) 2019-12-09
CA3058588C (en) 2021-11-09
US20200377509A1 (en) 2020-12-03
AR111199A1 (es) 2019-06-12
EP3601260A1 (en) 2020-02-05
CA3058588A1 (en) 2018-10-04
MX2019011782A (es) 2020-02-10

Similar Documents

Publication Publication Date Title
US10968231B2 (en) Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders
US11186565B2 (en) Aromatic compound
JP6529649B2 (ja) 縮合複素環化合物
JP6458054B2 (ja) 複素環化合物
DK3031799T3 (en) AROMATIC CONNECTION
US9975903B2 (en) Condensed heterocyclic compound
WO2016121782A1 (ja) スルホンアミド化合物
EP3275874B1 (en) Fused heterocyclic compound
HK40015122A (en) Aromatic compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211201

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211207

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20220426